Изучение ассоциации полиморфных маркеров генов CRP, IL6, IL10, TNF и LTA с развитием неблагоприятного исхода у больных, перенесших острый коронарный синдром
Диссертация
Сердечно-сосудистые заболевания (ССЗ) являются лидирующей причиной смертности во всём мире: ни по какой другой причине ежегодно не умирает столько людей, сколько от ССЗ. По данным Всемирной организации здравоохранения, в 2004 году от ССЗ умерло 17,1 миллиона человек, что составило 29% всех случаев смерти в мире. Согласно прогнозам, в 2030 году около 23,6 миллионов человек умрёт от ССЗ, главным… Читать ещё >
Список литературы
- ВОЗ | Сердечно-сосудистые заболевания (http://www.who.int/mediacentre /factsheets/fs317/ru/index.html).
- Оганов Р.Г., Масленникова Г. Я. 2007. Демографическая ситуация и сердечно-сосудистые заболевания в России: пути решения проблем. Кардиоеаскулярная терапия и профилактика. 6 (8), 7−14.
- Оганов Р., Масленникова Г. 2003. Вклад сердечно-сосудистых и других неинфекционных заболеваний в здоровье населения России. Сердце. 2 (2), 58−61.
- Goldbourt U., Faire U.D., Berg К. 1994. Genetic Factors in Coronary Heart Disease. 1й издание. Springer- .
- Сидоренко Б.А., Затейщиков Д. А., Минушкина JI.O. 2009. Кафедра кардиологии и общей терапии: исследования генетики сердечнососудистых заболеваний. Кремлевская медиг^ина. Клинический вестник. (2).
- Закирова Н.Э., Хафизов Н. Х., Карамова И. М., Закирова А. Н., Оганов Р. Г. 2007. Иммуновоспалительные реакции при ишемической болезни сердца. Рациональная фармакотерапия в кардиологии. 3 (2), 16−19.
- Титов В.Н. 1999. Общность атеросклероза и воспаления: специфичность атеросклероза как воспалительного процесса. Росс, кардиол. журн. (5), 24−29.
- Затейщиков Д.А., Королёва О. С. 2007. Биомаркеры в кардиологии: регистрация внутрисосудистого воспаления. Фарматека. (8), 30−36.
- Paoletti R., Gotto A.M., Hajjar D.P. 2004. Inflammation in Atherosclerosis and Implications for Therapy. Circulation. 109 (23suppll), 111−20−26.
- Pratt R.E., Dzau V.J. 1999. Genomics and hypertension: concepts, potentials, and opportunities. Hypertension. 33 (1 Pt 2), 238−247.
- Алтухов Ю.П., Салменкова E.A. 2002. Полиморфизм ДНК в популяционной генетике. Генетика. 38 (2), 1173−1195.
- Свердлов Е.Д. 2009. Очерки структурной молекулярной генетики. Москва: Наука- 1.
- Jeffreys A.J., Allen M.J., Armour J.A., et al. 1995. Mutation processes at human minisatellites. Electrophoresis. 16(9), 1577−1585.
- Pennisi Е. 1998. A closer look at SNPs suggests difficulties. Science. 281 (5384), 1787−1789.
- Crawford D.C., Akey D.T., Nickerson D.A. 2005. The patterns of natural variation in human genes. Annu Rev Genomics Hum Genet. 6, 287−312.
- Sherry S.T., Ward M.H., Kholodov M., et al. 2001. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 29 (1), 308−311.
- Ребриков Д.В., Саматов Г. А., Трофимов Д. Ю., Семёнов П. А. 2009. ПЦР в реальном времени. Москва: БИНОМ- .
- Kleppe К., Ohtsuka Е., Kleppe R., Molineux I., Khorana H.G. 1971. Studies on polynucleotides. XCVI. Repair replications of short synthetic DNA’s as catalyzed by DNA polymerases. J. Mol. Biol. 56 (2), 341−361.
- Saiki R.K., Scharf S., Faloona F., et al. 1985. Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science. 230 (4732), 1350−1354.
- Higuchi R., Dollinger G., Walsh P. S., Griffith R. 1992. Simultaneous amplification and detection of specific DNA sequences. Biotechnology (N.Y.). 10(4), 413−417.
- Higuchi R., Fockler C., Dollinger G., Watson R. 1993. Kinetic PCR analysis: real-time monitoring of DNA amplification reactions. Biotechnology (N.Y.). 11 (9), 1026−1030.
- VanGuilder H.D., Vrana K.E., Freeman W.M. 2008. Twenty-five years of quantitative PCR for gene expression analysis. BioTechniques. 44 (5), 619 626.
- Nolan T., Hands R.E., Bustin S.A. 2006. Quantification of mRNA using realtime RT-PCR. Nat Protoc. 1 (3), 1559−1582.
- Holland P.M., Abramson R.D., Watson R., Gelfand D.H. 1991. Detection of specific polymerase chain reaction product by utilizing the 5'—3' exonuclease activity of Thermus aquaticus DNA polymerase. Proc. Natl Acad. Sci. U.S.A. 88 (16), 7276−7280.
- Rozen S., Skaletsky H. 2000. Primer3 on the WWW for general users and for biologist programmers. Methods Mol. Biol. 132, 365−386.
- Untergasser A., Nijveen H., Rao X., et al. 2007. Primer3Plus, an enhanced web interface to Primer3. Nucleic Acids Res. 35, W71−74.
- Chen S.H., Lin C.Y., Cho C.S., Lo C.Z., Hsiung C.A. 2003. Primer Design Assistant (PDA): A web-based primer design tool. Nucleic Acids Res. 31 (13), 3751−3754.
- Wangkumhang P., Chaichoompu K., Ngamphiw C., et al. 2007. WASP: a Web-based Allele-Specific PCR assay designing tool for detecting SNPs and mutations. BMC Genomics. 8, 275.
- Tsai M.-F., Lin Y.-J., Cheng Y.-C., et al. 2007. PrimerZ: streamlined primer design for promoters, exons and human SNPs. Nucleic Acids Res. 35, W63−65.
- Weckx S., De Rijk P., Van Broeckhoven C., Del-Favero J. 2005. SNPbox: a modular software package for large-scale primer design. Bioinformatics. 21 (3), 385−387.
- Chang H.-W., Chuang L.-Y., Cheng Y.-H., et al. 2009. Prim-SNPing: a primer designer for cost-effective SNP genotyping. BioTechniques. 46 (6), 421−431.
- Niu Т., Hu Z. 2004. SNPicker: a graphical tool for primer picking in designing mutagenic endonuclease restriction assays. Bioinformatics. 20 (17), 3263−3265.
- Little S. 2001. Amplification-refractory mutation system (ARMS) analysis of point mutations. Curr Protoc Hum Genet. Chapter 9, Unit 9.8.
- Иванов В.И. 2009. Геномика — медицине. Москва: Академкнига- .
- Brown D.L., Gorin М.В., Weeks D.E. 1994. Efficient strategies for genomic searching using the affected-pedigree-member method of linkage analysis. Am. J. Hum. Genet. 54 (3), 544−552.
- Ghosh S., Collins F.S. 1996. The geneticist’s approach to complex disease. Annu. Rev. Med. 47, 333−353.
- Hall J.M., Lee M.K., Newman В., et al. 1990. Linkage of early-onset familial breast cancer to chromosome 17q21. Science. 250 (4988), 1684−1689.
- Thomson G. 1995. Mapping disease genes: family-based association studies. Am. J. Hum. Genet. 57 (2), 487−498.
- Пузырёв В.П., Степанов В.A. 1997. Патологическая анатомия генома человека. Новосибирск: Наука- .
- Горбунова В.Н. 1999. Молекулярные основы медицинской генетики. Санкт-Петербург: Интермедика- .
- Сох N.J., Bell G.I. 1989. Disease associations. Chance, artifact, or susceptibility genes? Diabetes. 38 (8), 947 -950.
- Карпов P.C., Дудко B.A. 1998. Атеросклероз: патогенез, клиника, функциональная диагностика, лечение. Томск: STT- .
- Hamsten A., Wiman В., de Faire U., Blomback M. 1985. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N. Engl. J. Med. 313 (25), 1557−1563.
- Li H., Cybulsky M., Gimbrone M., Libby P. 1993. An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. Arterioscler Thromb Vase Biol. .
- Hansson G.K. 2005. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352 (16), 1685−1695.
- Gu L., Okada Y., Clinton S.K., et al. 1998. Absence of monocytechemoattractant protein-1 reduces atherosclerosis in low density lipoproteinireceptor-deficient mice. Mol. Cell. 2 (2), 275−281.
- Boring L., Gosling J., Cleary M., Charo I.F. 1998. Decreased lesion formation in CCR2-/- mice reveals a role for chemoldnes in the initiation of atherosclerosis. Nature. 394 (6696), 894−897.
- Mach F., Sauty A., Iarossi A.S., et al. 1999. Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J. Clin. Invest. 104 (8), 1041−1050.
- Smith J.D., Trogan E., Ginsberg ML, et al. 1995. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc. Natl. Acad. Sci. U.S.A. 92 (18), 8264−8268.
- Qiao J.H., Tripathi J., Mishra N.K., et al. 1997. Role of macrophage colony-stimulating factor in atherosclerosis: studies of osteopetrotic mice. Am. J. Pathol. 150(5), 1687−1699.
- Hansson G., Libby P. 1996. The role of the lymphocyte. In: Fuster V, Ross R, Topol E, eds. B Atherosclerosis and Coronary Artery Disease. New York, NY: Lippincott-Raven-, 557−568.
- Ross R. 1999. Atherosclerosis—an inflammatory disease. N. Engl. J. Med. 340 (2), 115−126.
- Libby P., Geng Y.J., Aikawa M., et al. 1996. Macrophages and atherosclerotic plaque stability. Curr. Opin. Lipidol. 1 (5), 330−335.
- Libby P. 2001. Current concepts of the pathogenesis of the acute coronary3syndromes. Circulation. 104 (3), 365−372.
- Libby P., Simon D.I. 2001. Inflammation and thrombosis: the clot thickens. Circulation. 103 (13), 1718−1720.
- Berliner J., Leitinger N., Watson A., et al. 1997. Oxidized lipids in atherogenesis: formation, destruction and action. Thromb. Haemost. 78 (1), 195−199.
- Williams K.J., Tabas I. 1998. The response-to-retention hypothesis of atherogenesis reinforced. Curr. Opin. Lipidol. 9 (5), 471−474.
- Witztum J.L., Berliner J.A. 1998. Oxidized phospholipids and isoprostanes in atherosclerosis. Curr. Opin. Lipidol. 9 (5), 441−448.
- Stemme S., Faber B., Holm J., et al. 1995. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc. Natl. Acad Sei. U.S.A. 92 (9), 3893−3897.
- Hazen S.L., Hsu F.F., Gaut J.P., Crowley J.R., Heinecke J.W. 1999. Modification of proteins and lipids by myeloperoxidase. Meth. Enzymol. 300, 88−105.
- Sugiyama S., Okada Y., Sukhova G.K., et al. 2001. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am. J. Pathol. 158 (3), 879−891.
- Dichtl W., Nilsson L., Goncalves I., et al. 1999. Very Low-Density Lipoprotein Activates Nuclear Factor-{kappa}B in Endothelial Cells. Circ Res. 84 (9), 1085−1094.
- Mackness M.I., Mackness B., Durrington P.N., et al. 1998. Paraoxonase and coronary heart disease. Curr. Opin. Lipidol. 9 (4), 319−324.
- Lee J.M.S., Choudhury R.P. 2010. Atherosclerosis regression and high-density lipoproteins. Expert Rev Cardiovasc Ther. 8 (9), 1325−1334.
- Griendling K.K., Ushio-Fukai M., Lassegue B., Alexander R.W. 1997. Angiotensin II signaling in vascular smooth muscle. New concepts. Hypertension. 29 (1 Pt 2), 366−373.
- Kranzhofer R., Schmidt J., Pfeiffer C.A., et al. 1999. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler. Thromb. Vase. Biol. 19 (7), 1623−1629.
- Tummala P.E., Chen X.L., Sundell C.L., et al. 1999. Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: A potential link between the renin-angiotensin system and atherosclerosis. Circulation. 100(11), 1223−1229.
- Schmidt A.M., Yan S.D., Wautier J.L., Stern D. 1999. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ. Res. 84 (5), 489−497.
- Baynes J.W., Thorpe S.R. 1999. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes. 48 (1), 1−9.
- Libby P., Egan D., Skarlatos S. 1997. Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research. Circulation. 96 (11), 4095−4103.
- Danesh J., Collins R., Peto R. 1997. Chronic infections and coronary heart disease: is there a link? Lancet. 350 (9075), 430−436.
- Kol A., Bourcier Т., Lichtman A.H., Libby P. 1999. Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages. J. Clin. Invest. 103 (4), 571−577.
- Оганов Р.Г., Мамедов M.H. 2009. Национальные клинические рекомендации Всероссийского научного общества кардиологов. Москва: «МЕДИ Экспо" — .
- Hersi A., Fu Y., Wong В., et al. 2003. Does the discharge ECG provide additional prognostic insight (s) in non-ST elevation ACS patients from that acquired on admission? Eur. Heart J. 24 (6), 522−531.
- Kofoed S.C., Wittrup H.H., Sillesen H., Nordestgaard B.G. 2003. Fibrinogen predicts ischaemic stroke and advanced atherosclerosis but not echolucent, rupture-prone carotid plaques: the Copenhagen City Heart Study. Eur. Heart J. 24 (6), 567−576.
- Heras M., Marrugat J., Aros F., et al. 2006. Reduction in acute myocardial infarction mortality over a five-year period. Rev Esp Cardiol. 59 (3), 200 208.
- Шевченко О., Мишнев О., Шевченко О., others. 2005. Ишемическая болезнь сердца. М, Реафарм. .
- Furberg C.D. 1987. Secondary prevention trials after acute myocardial infarction. The American Journal of Cardiology. 60 (2), 28−32.
- Keavney B. 2002. Genetic epidemiological studies of coronary heart disease. Int J Epidemiol. 31 (4), 730−736.
- Galvani M., Ferrini D., Ottani F., Eisenberg P.R. 1999. Early risk stratification of unstable angina/non-Q myocardial infarction: biochemical markers of coronary thrombosis. Int. J. Cardiol. 68 Suppl 1, S55−61.
- Hamm C.W. 2004. Paradigms in treatment of myocardial infarction. Anaesthesist. 53 (5), 409−410.
- Van de Werf F., Bax J., Betriu A., et al., Societa Europea di Cardiologia. 2009. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. G Ital Cardiol (Rome). 10 (7), 450−489.
- Andersen H.R., Nielsen T.T., Rasmussen K., et al. 2003. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N. Engl. J. Med. 349 (8), 733−742.
- Keeley E.C., Boura J.A., Grines C.L. 2003. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 361 (9351), 13−20.
- Zeymer U., Gitt A., Senges J. 2005. Akuter ST-Strecken-Hebungs-Myokardinfarkt, Aktuelle Versorgungssituation der Patienten in Deutschland. Herz. 30 (3), 241−248.
- Pitsavos C., Kourlaba G., Panagiotakos D.B., Stefanadis C. 2006. Factors associated with delay in seeking health care for hospitalized patients with105acute coronary syndromes: the GREECS study. Hellenic J Cardiol. 47 (6), 329−336.
- Faire U.D., Pedersen N. 1994. Studies of twins and adoptees in coronary artery disease. In: Genetic factors in coronary heart disease. Kluver Acad. Pub., 55−68.
- Tillett W.S., Francis T. 1930. Serological reactions in pneumonia with a nonprotein somatic fraction of pneumococcus. J. Exp. Med. 52 (4), 561−571.
- Pepys M.B., Baltz M.L. 1983. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv. Immunol. 34, 141−212.
- Bassuk S.S., Rifai N., Ridker P.M. 2004. High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol. 29 (8), 439−493.
- Ridker P.M., Danielson E., Rifai N., Glynn R.J. 2006. Valsarian, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial. Hypertension. 48 (1), 73−79.
- Danesh J., Whincup P., Walker M., et al. 2000. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ. 321 (7255), 199−204.
- Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. 2000. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342 (12), 836−843.
- Ridker P.M., Rifai N., Rose L., Buring J.E., Cook N.R. 2002. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med. 347 (20), 15 571 565.
- Buckley D.I., Fu R., Freeman M., Rogers K., Helfand M. 2009. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force. Ann. Intern. Med. 151 (7), 483−495.
- Memon L., Spasojevic-Kalimanovska V., Bogavac-Stanojevic N., et al. 2006. Association of C-reactive protein with the presence and extent of angiographically verified coronary artery disease. Tohoku J. Exp. Med. 209 (3), 197−206.
- Floyd-Smith G., Whitehead A.S., Colten H.R., Francke U. 1986. The human C-reactive protein gene (CRP) and serum amyloid P component gene (APCS) are located on the proximal long arm of chromosome 1. Immunogenetics. 24 (3), 171−176.
- Walsh M.T., Divane A., Whitehead A.S. 1996. Fine mapping of the human pentraxin gene region on chromosome lq23. Immunogenetics. 44 (1), 62−69.
- Woo P., Korenberg J.R., Whitehead A.S. 1985. Characterization of genomic and complementary DNA sequence of human C-reactive protein, and comparison with the complementary DNA sequence of serum amyloid P component. J. Biol. Chem. 260 (24), 13 384−13 388.
- Lei K.J., Liu T., Zon G., et al. 1985. Genomic DNA sequence for human C-reactive protein. J. Biol. Chem. 260 (24), 13 377−13 383.
- Goldman N.D., Liu T., Lei K.J. 1987. Structural analysis of the locus containing the human C-reactive protein gene and its related pseudogene. J. Biol. Chem. 262 (15), 7001−7005.
- Kushner I., Jiang S.L., Zhang D., Lozanski G., Samols D. 1995. Do post-transcriptional mechanisms participate in induction of C-reactive protein and serum amyloid A by IL6 and IL-1? Ann. N. Y. Acad. Sei. 762, 102−107.
- Berger P., McConnell J.P., Nunn M., et al. 2002. C-reactive protein levels are influenced by common IL-1 gene variations. Cytokine. 17 (4), 171−174.
- Latkovskis G., Licis N., Kalnins U. 2004. C-reactive protein levels and common polymorphisms of the interleukin-1 gene cluster and interleukin-6 gene in patients with coronary heart disease. Eur. J. Immunogenet. 31 (5), 207−213.
- Vickers M.A., Green F.R., Terry C., et al. 2002. Genotype at a promoter polymorphism of the interleukin-6 gene is associated with baseline levels of plasma C-reactive protein. Cardiovasc. Res. 53 (4), 1029−1034.
- Crawford D.C., Sanders C.L., Qin X., et al. 2006. Genetic variation is associated with C-reactive protein levels in the Third National Health and Nutrition Examination Survey. Circulation. 114 (23), 2458−2465.
- Balistreri C.R., Vasto S., Listi F., et al. 2006. Association between +1059G/C CRP polymorphism and acute myocardial infarction in a cohort of patients from Sicily: a pilot study. Ann. N. Y. Acad. Sei. 1067, 276−281.
- Davey Smith G., Lawlor D.A., Harbord R., et al. 2005. Association of C-reactive protein with blood pressure and hypertension: life course confounding and mendelian randomization tests of causality. Arterioscler. Thromb. Vase. Biol. 25 (5), 1051−1056.
- Miller D.T., Zee R.Y.L., Suk Danik J., et al. 2005. Association of Common CRP Gene Variants with CRP Levels and Cardiovascular Events. Annals of Human Genetics. 69 (6), 623−638.
- Russell A.I., Cunninghame Graham D.S., Shepherd C., et al. 2004. Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum. Mol. Genet. 13 (1), 137 147.
- Suk Danik J., Chasman D.I., Cannon C.P., et al. 2006. Influence of Genetic Variation in the C-Reactive Protein Gene on the Inflammatory Response During and After Acute Coronary Ischemia. Ann Human Genet. 70 (6), 705 716.
- Suk H.J., Ridker P.M., Cook N.R., Zee R.Y.L. 2005. Relation of polymorphism within the C-reactive protein gene and plasma CRP levels. Atherosclerosis. 178 (1), 139−45.
- Zee R.Y.L., Ridker P.M. 2002. Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis. Atherosclerosis. 162 (1), 217−219.
- Brull D.J., Serrano N., Zito F., et al. 2003. Human CRP Gene Polymorphism Influences CRP Levels: Implications for the Prediction and Pathogenesis of Coronary Heart Disease. Arterioscler Thromb Vase Biol. 23 (11), 2063−2069.
- Kovacs A., Green F., Hansson L.-O., et al. 2005. A novel common single nucleotide polymorphism in the promoter region of the C-reactive protein gene associated with the plasma concentration of C-reactive protein. Atherosclerosis. 178 (1), 193−198.
- Kardys I., de Maat M.P.M., Uitterlinden A.G., Hofman A., Witteman J.C.M. 2006. C-reactive protein gene haplotypes and risk of coronary heart disease: the Rotterdam Study. European Heart Journal. 27 (11), 1331 -1337.
- Casas J.P., Shah Т., Cooper J., et al. 2006. Insight into the nature of the CRP-coronary event association using Mendelian randomization. Int J Epidemiol. 35 (4), 922−931.
- Шахнович P.M., Сухинина T.C., Барсова P.M., et al. 2010. Полиморфизм C1444T гена CRP и концентрация С-реактивного белка в сыворотке крови при инфаркте миокарда. Кардиология. (8), 4−12.
- Worns М.А., Victor А., Galle P.R., Hohler Т. 2006. Genetic and environmental contributions to plasma C-reactive protein and interleukin-6 levels—a study in twins. Genes Immun. 7 (7), 600−605.
- MacGregor A. J., Gallimore J.R., Spector T.D., Pepys M.B. 2004. Genetic effects on baseline values of C-reactive protein and serum amyloid a protein: a comparison of monozygotic and dizygotic twins. Clin. Chem. 50 (1), 130 134.
- Retterstol L., Eikvar L., Berg K. 2003. A twin study of C-Reactive Protein compared to other risk factors for coronary heart disease. Atherosclerosis. 169 (2), 279−282.
- Weber J.L., Kwitek A.E., May P.E. 1990. Dinucleotide repeat polymorphism at the CRP locus. Nucleic Acids Res. 18 (15), 4635.
- Cao H., Hegele R.A. 2000. Human C-reactive protein (CRP) 1059G/C polymorphism. J. Hum. Genet. 45 (2), 100−101.
- Hegele R.A., Ban M.R., Young T.K. 2001. Serum C-reactive protein in Canadian Inuit and its association with genetic variation on chromosome lq21. Clin. Chem. 47 (9), 1707−1709.
- Crawford D.C., Yi Q., Smith J.D., et al. 2006. Allelic spectrum of the natural variation in CRP. Hum. Genet. 119 (5), 496−504.
- Chen J., Zhao J., Huang J., et al. 2005. -717A>G polymorphism of human C-reactive protein gene associated with coronary heart disease in ethnic Han Chinese: the Beijing atherosclerosis study. J. Mol. Med. 83 (1), 72−78.
- Wang Q., Hunt S.C., Xu Q., et al. 2006. Association study of CRP gene polymorphisms with serum CRP level and cardiovascular risk in the NHLBI Family Heart Study. Am. J. Physiol. Heart Circ. Physiol. 291 (6), H2752−2757.
- Morita A., Nakayama T., Doba N., Hinohara S., Soma M. 2006. Polymorphism of the C-reactive protein (CRP) gene is related to serum CRP Level and arterial pulse wave velocity in healthy elderly Japanese. Hypertens. Res. 29 (5), 323−331.
- Lange L.A., Carlson C.S., Hindorff L.A., et al.
- Heinrich P.C., Castell J.V., Andus T. 1990. Interleukin-6 and the acute phase response. Biochem J. 265 (3), 621−636.
- Bataille Reg., Klein B. 1992. C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo. Arthritis & Rheumatism. 35 (8), 982 983.
- Pinkney J.H., Coppack S.W., Mohamed-Ali. 1998. Adipose tissue as an endocrine and paracrine organ. Int J Obesity. 22 (12), 1145−1158.
- Vallance P., Collier J., Bhagat K. 1997. Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link? Lancet. 349 (9062), 1391−1392.
- Harris T.B., Ferrucci L., Tracy R.P., et al. 1999. Associations of elevated Interleukin-6 and C-Reactive protein levels with mortality in the elderly. The American Journal of Medicine. 106 (5), 506−512.
- Tappia P. S., Troughton K.L., Langley-Evans S.C., Grimble R.F. 1995. Cigarette smoking influences cytokine production and antioxidant defences. Clin. Sci. 88 (4), 485−489.
- Fantuzzi G., Zheng H., Faggioni R., et al. 1996. Effect of endotoxin in IL-1 beta-deficient mice. J. Immunol. 157 (1), 291−296.
- Marino M.W., Dunn A., Grail D., et al. 1997. Characterization of tumor necrosis factor-deficient? mice. Proceedings of the National Academy of Sciences of the United States of America. 94 (15), 8093 -8098.
- Dan K., Gomi S., Inokuchi K., et al. 1995. Effects of interleukin-1 and tumor necrosis factor on megakaryocytopoiesis: mechanism of reactive thrombocytosis. Acta Haematol. 93 (2−4), 67−72.
- Van Snick J. 1990. Interleukin-6: an overview. Annu. Rev. Immunol. 8, 253 278.
- Hardardottir I., Griinfeld C., Feingold K.R. 1994. Effects of endotoxin and cytokines on lipid metabolism. Curr. Opin. Lipidol. 5 (3), 207−215.
- Greenberg A.S., Nordan R.P., Mcintosh J., et al. 1992. Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: a possible role for interleukin 6 in cancer cachexia. Cancer Res. 52(15), 4113−4116.
- Kanemaki T., Kitade H., Kaibori M., et al. 1998. Interleukin lbeta and interleukin 6, but not tumor necrosis factor alpha, inhibit insulin-stimulated glycogen synthesis in rat hepatocytes. Hepatology. 27 (5), 1296−1303.
- Bhagat K., Vallance P. 1997. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation. 96 (9), 3042−3047.
- Romano M., Sironi M., Toniatti C., et al. 1997. Role of IL6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity. 6 (3), 315−325.
- Robinson L.J., Busconi L., Michel T. 1995. Agonist-modulated palmitoylation of endothelial nitric oxide synthase. J. Biol. Chem. 270 (3), 995−998.
- Castell J.V., Geiger Т., Gross V., et al. 1988. Plasma clearance, organ distribution and target cells of interleukin-6/hepatocyte-stimulating factor in the rat. Eur. J. Biochem. 177 (2), 357−361.
- Ray A., Tatter S.B., May L.T., Sehgal P.B. 1988. Activation of the human «beta 2-interferon/hepatocyte-stimulating factor/interleukin 6» promoter by cytokines, viruses, and second messenger agonists. Proc. Natl. Acad. Sci. U.S.A. 85 (18), 6701−6705.
- Isshiki H., Akira S., Tanabe O., et al. 1990. Constitutive and interleukin-1 (IL-l)-inducible factors interact with the IL-1 -responsive element in the IL6 gene. Mol. Cell. Biol. 10 (6), 2757−2764.
- Matsusaka Т., Fujikawa K., Nishio Y., et al. 1993. Transcription factors NF-IL6 • and NF-kappa В synergistically activate transcription of the inflammatory cytokines, interleukin 6 and interleukin 8. Proc. Natl. Acad. Sci. U.S.A. 90(21), 10 193−10 197.
- Ray A., Prefontaine K.E. 1994. Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa В and the glucocorticoid receptor. Proc. Natl. Acad. Sci. U.S.A. 91 (2), 752−756.
- Ray A., Prefontaine K.E., Ray P. 1994. Down-modulation of interleukin-6 gene expression by 17 beta-estradiol in the absence of high affinity DNA binding by the estrogen receptor. J. Biol. Chem. 269 (17), 12 940−12 946.
- Шевченко A.B., Голованова O.B., Коненков В.И., et al. 2009. Анализ взаимосвязи полиморфизма гена IL6 (-174 G/C) и классических факторов риска у пациентов с острым инфарктом миокарда в анамнезе. Медицинская иммунология. 11 (6), 557−566.
- Jones K.G., Brull D.J., Brown L.C., et al. 2001. Interleukin-6 (IL6) and the prognosis of abdominal aortic aneurysms. Circulation. 103 (18), 2260−2265.
- Rauramaa R., Vaisanen S.B., Luong L.A., et al. 2000. Stromelysin-1 and interleukin-6 gene promoter polymorphisms are determinants of asymptomatic carotid artery atherosclerosis. Arterioscler. Thromb. Vase. Biol. 20 (12), 2657−2662.
- Rundek T., Elkind M.S., Pittman J., et al. 2002. Carotid intima-media thickness is associated with allelic variants of stromelysin-1, interleukin-6, and hepatic lipase genes: the Northern Manhattan Prospective Cohort Study. Stroke. 33 (5), 1420−1423.
- Basso F., Lowe G.D.O., Rumley A., McMahon A.D., Humphries S.E. 2002. Interleukin-6 -174G>C Polymorphism and Risk of Coronary Heart Disease in West of Scotland Coronary Prevention Study (WOSCOPS). Arterioscler Thromb Vase Biol. 22 (4), 599−604.
- Flex A., Gaetani E., Pola R., et al. 2002. The -174 G/C polymorphism of the interleukin-6 gene promoter is associated with peripheral artery occlusive disease. Eur J Vase Endovasc Surg. 24 (3), 264−268.
- Pola R., Gaetani E., Flex A., et al. 2002. -174 G/C interleukin-6 gene polymorphism and increased risk of multi-infarct dementia: a case-control study. Exp. Gerontol. 37 (7), 949−955.
- Chapman C.M.L., Beilby J.P., Humphries S.E., et al. 2003. Association of an allelic variant of interleukin-6 with subclinical carotid atherosclerosis in an Australian community population. Eur. Heart J. 24 (16), 1494−1499.
- Manginas A., Tsiavou A., Chaidaroglou A., et al. 2008. Inflammatory cytokine gene variants in coronary artery disease patients in Greece. Coron. Artery Dis. 19 (8), 575−582.
- Sie M.P.S., Mattace-Raso F.U.S., Uitterlinden A.G., et al. 2008. The interleukin-6−174 G/C promoter polymorphism and arterial stiffness- the Rotterdam Study. Vase Health Risk Manag. 4 (4), 863−9.
- Aker S., Bantis C., Reis P., et al. 2009. Influence of interleukin-6 G-174C gene polymorphism on coronary artery disease, cardiovascular complications and mortality in dialysis patients. Nephrol. Dial. Transplant. 24 (9), 28 472 851.
- Fiorentino D.F., Zlotnik A., Mosmann T.R., Howard M., O’Garra A. 1991. ILIO inhibits cytokine production by activated macrophages. J. Immunol. 147 (11), 3815−3822.
- Fiorentino D.F., Zlotnik A., Vieira P., et al. 1991. ILIO acts on the antigen-presenting cell to inhibit cytokine production by Thl cells. J. Immunol. 146 (10), 3444−3451.
- Moore K.W., de Waal Malefyt R., Coffman R.L., O’Garra A. 2001. Iterleukin-10 and the Interleukin-10 receptor. Annu. Rev. Immunol. 19 (1), 683−765.
- Wang P., Wu P., Siegel M.I., Egan R.W., Billah M.M. 1995. Interleukin (IL)-10 Inhibits Nuclear Factor B (NFB) Activation in Human Monocytes. Journal of Biological Chemistry. 270 (16), 9558−9563.
- Levens J.M., Gordon J., Gregory C.D. 2000. Micro-environmental factors in the survival of human B-lymphoma cells. Cell Death Differ. 1 (1), 59−69.
- Moore K., Vieira P., Fiorentino D., et al. 1990. Homology of cytokine synthesis inhibitory factor (IL10) to the Epstein-Barr virus gene BCRFI. Science. 248 (4960), 1230 -1234.
- Howard M., O’Garra A. 1992. Biological properties of interleukin 10. Immunology Today. 13 (6), 198−200.
- Platzer C., Volk H.D., Platzer M. 1994. 5' noncoding sequence of human IL10 gene obtained by oligo-cassette PCR walking. DNA Seq. 4 (6), 399−401.
- Platzer C., Docke W.-D., Volk H.-D., Prosch S. 2000. Catecholamines trigger IL10 release in acute systemic stress reaction by direct stimulation of its promoter/enhancer activity in monocytic cells. Journal ofNeuroimmunology. 105 (1), 31−38.
- Walter M.R. 2002. Structure of Interleukin-10/Interleukin-10R1 Complex: A Paradigm for Class 2 Cytokine Activation. IR. 26 (1−3), 303−308.
- Standiford T.J., Strieter R.M., Lukacs N.W., ICunkel S.L. 1995. Neutralization of IL10 increases lethality in endotoxemia. Cooperative effects of macrophage inflammatory protein-2 and tumor necrosis factor. J. Immunol. 155 (4), 2222−2229.
- Lang R., Rutschman R.L., Greaves D.R., Murray P.J. 2002. Autocrine deactivation of macrophages in transgenic mice constitutively overexpressing IL10 under control of the human CD68 promoter. J. Immunol. 168 (7), 34 023 411.
- Clarke C.J., Hales A., Hunt A., Foxwell B.M. 1998. ILlO-mediated suppression of TNF-alpha production is independent of its ability to inhibit NF kappa B activity. Eur. J. Immunol. 28 (5), 1719−1726.
- Schottelius A.J.G., Mayo M.W., Sartor R.B., Baldwin A.S. 1999. Interleukin-10 Signaling Blocks Inhibitor of kB Kinase Activity and Nuclear Factor kB DNA Binding. Journal of Biological Chemistry. 21A (45), 31 868 -31 874.
- Ito S., Ansari P., Sakatsume M., et al. 1999. Interleukin-10 inhibits expression of both interferon alpha- and interferon gamma- induced genes by suppressing tyrosine phosphorylation of STAT1. Blood. 93 (5), 1456−1463.
- Donnelly R.P., Dickensheets H., Finbloom D.S. 1999. The Interleukin-10 Signal Transduction Pathway and Regulation of Gene Expression in Mononuclear Phagocytes. / interferon cytokine res. 19 (6), 563−573.
- Berlato C., Cassatella M.A., Kinjyo I., et al. 2002. Involvement of suppressor of cytokine signaling-3 as a mediator of the inhibitory effects of IL10 on lipopolysaccharide-induced macrophage activation. J. Immunol. 168 (12), 6404−6411.
- Lee T.-S., Chau L.-Y. 2002. Heme oxygenase-1 mediates the antiinflammatory effect of interleukin-10 in mice. Nat Med. 8 (3), 240−246.
- Bogdan C., Vodovotz Y., Nathan C. 1991. Macrophage deactivation by interleukin 10. The Journal of Experimental Medicine. VIA (6), 1549 -1555.
- Kwon O.J. 1997. The role of nitric oxide in the immune response of tuberculosis. J. Korean Med. Sci. 12 (6), 481−487.
- Dandona P., Mohanty P., Hamouda W., et al. 1999. Effect of dexamethasone on reactive oxygen species generation by leukocytes and plasma interleukin-10 concentrations: a pharmacodynamic study. Clin. Pharmacol. Ther. 66 (1), 58−65.
- Gunnett C.A., Heistad D.D., Berg D.J., Faraci F.M. 2000. IL10 deficiency increases superoxide and endothelial dysfunction during inflammation. Am. J. Physiol. Heart Circ. Physiol. 279 (4), HI555−1562.
- Keel M., Ungethum U., Steckholzer U., et al. 1997. Interleukin-10 counterregulates proinflammatory cytokine-induced inhibition of neutrophil apoptosis during severe sepsis. Blood. 90 (9), 3356−3363.
- Lacraz S., Nicod L.P., Chicheportiche R., Welgus H.G., Dayer J.M. 1995. IL10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J. Clin. Invest. 96 (5), 2304−2310.
- Anguera I., Miranda-Guardiola F., Bosch X., et al. 2002. Elevation of serum ' levels of the anti-inflammatory cytokine interleukin-10 and decreased risk of coronary events in patients with unstable angina. Am. Heart J. 144 (5), 811 817.
- Smith D.A., Irving S.D., Sheldon J., Cole D., Kaski J.C. 2001. Serum Levels of the Antiinflammatory Cytokine Interleukin-10 Are Decreased in Patients With Unstable Angina. Circulation. 104 (7), 746−749.
- Mizia-Stec K., Gasior Z., Zahorska-Markiewicz B., et al. 2003. Serum tumour necrosis factor-alpha, interleukin-2 and interleukin-10 activation in stable angina and acute coronary syndromes. Coron. Artery Dis. 14 (6), 431 438.
- Kube D., Rieth H., Eskdale J., Kremsner P.G., Gallagher G. 2001. Structural characterisation of the distal 5' flanking region of the human interleukin-10 gene. Genes Immun. 2 (4), 181−190.
- Gibson A.W., Edberg J.C., Wu J., et al. 2001. Novel single nucleotide polymorphisms in the distal ILIO promoter affect ILIO production and enhance the risk of systemic lupus erythematosus. J. Immunol. 166 (6), 39 153 922.
- Eskdale J., Gallagher G., Verweij C.L., et al. 1998. Interleukin 10 secretion in relation to human ILIO locus haplotypes. Proc. Natl. Acad. Sei. U.S.A. 95 (16), 9465−9470.
- Heiskanen M., Kahonen M., Hurme M., et al. 2010. Polymorphism in the ILIO promoter region and early markers of atherosclerosis: the Cardiovascular Risk in Young Finns Study. Atherosclerosis. 208 (1), 190 196.
- Fei G.-Z., Svenungsson E., Frostegard J., Padyukov L. 2004. The A-1087IL10 allele is associated with cardiovascular disease in SLE. Atherosclerosis. 177 (2), 409−414.
- Kahraman S., Yilmaz R., Arid M., et al. 2006. ILIO genotype predicts serum levels of adhesion molecules, inflammation and atherosclerosis in hemodialysis patients. J. Nephrol. 19 (1), 50−56.
- Donger C., Georges J.L., Nicaud V., et al. 2001. New polymorphisms in the interleukin-10 gene—relationships to myocardial infarction. Eur. J. Clin. Invest. 31 (1), 9−14.
- Koch W., Tiroch K., von Beckerath N., Schomig A., Kastrati A. 2003. Tumor necrosis factor-alpha, lymphotoxin-alpha, and interleukin-10 gene polymorphisms and restenosis after coronary artery stenting. Cytokine. 24 (4), 161−171.
- Oda K., Tanaka N., Arai T., et al. 2007. Polymorphisms in pro- and antiinflammatory cytokine genes and susceptibility to atherosclerosis: a pathological study of 1503 consecutive autopsy cases. Hum. Mol. Genet. 16 (6), 592−599.
- Spiegelman B.M., Hotamisligil G.S. 1993. Through thick and thin: Wasting, obesity, and TNFalpha. Cell. 73 (4), 625−627.
- Fiers W., Beyaert R., Brouckaert P., et al. 1987. Tumor necrosis factor: a potential antitumor agent? J. Interferon Res. 7 (5), 627−634.
- Loetscher H., Pan Y.-C.E., Lahm H.-W., et al. 1990. Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor. Cell. 61 (2), 351−359.
- Smith C., Davis T., Anderson D., et al. 1990. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science. 248 (4958), 1019−1023.
- Vandenabeele P., Declercq W., Beyaert R., Fiers W. 1995. Two tumour necrosis factor receptors: structure and function. Trends in Cell Biology. 5 (10), 392−399.
- Grell M., Douni E., Wajant H., et al. 1995. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell. 83 (5), 793−802.
- Grell M., Wajant H., Zimmermann G., Scheurich P. 1998. The type 1 receptor (CD 120a) is the high-affinity receptor for soluble tumor? necrosis? factor. Proc Natl Acad Sci US A. 95 (2), 570−575.1. OimeoK ¦mTe3X!7yp>-!
- Torre-Amione G., Kapadia S., Lee J., et al. 1995. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation. 92 (6), 1487−1493.
- Vassalli P. 1992. The Pathophysiology of Tumor Necrosis Factors. Annu. Rev. Immunol. 10 (1), 411−452.
- Kapadia S., Dibbs Z., Kurrelmeyer K., et al. 1998. The role of cytokines in the failing human heart. Cardiology Clinics. 16 (4), 645−656.
- Rauchhaus M., Coats A.J., Anker S.D. 2000. The endotoxin-lipoprotein hypothesis. The Lancet. 356 (9233), 930−933.
- Blick M., Sherwin S.A., Rosenblum M., Gutterman J. 1987. Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res. 47 (11), 2986−2989.
- Satoh M., Nakamura M., Tamura M., et al. 1997. Inducible Nitric Oxide Synthase and Tumor Necrosis Factor-Alpha in Myocardium in Human Dilated Cardiomyopathy. Journal of the American College of Cardiology. 29 (4), 716−724.
- Torre-Amione G., Kapadia S., Lee J., et al. 1996. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation. 93 (4), 704−711.
- Giroir B.P., Johnson J.H., Brown T., Allen G.L., Beutler B. 1992. The tissue distribution of tumor necrosis factor biosynthesis during endotoxemia. J. Clin. Invest. 90 (3), 693−698.
- Kapadia S., Lee J., Torre-Amione G., et al. 1995. Tumor necrosis factor-alpha gene and protein expression in adult feline myocardium after endotoxin administration. J. Clin. Invest. 96 (2), 1042−1052.
- Kapadia S.R., Oral H., Lee J., et al. 1997. Hemodynamic regulation of tumor necrosis factor-alpha gene and protein expression in adult feline myocardium. Circ. Res. 81 (2), 187−195.
- Yue P., Massie B.M., Simpson P.C., Long C.S. 1998. Cytokine expression increases in nonmyocytes from rats with postinfarction heart failure. Am. J. Physiol. 275 (1 Pt 2), H250−258.
- Meldrum MD D.R., Cleveland Jr M., Cain MD B.S., Meng MD P., Harken MD A.H. 1998. Increased Myocardial Tumor Necrosis Factor-alpha. in a Crystalloid-Perfused Model of Cardiac Ischemia-Reperfusion Injury. The Annals of Thoracic Surgery. 65 (2), 439−443.
- Ferrari R. 1998. Tumor necrosis factor in CHF: a double facet cytokine. Cardiovascular Research. 37 (3), 554 -559.
- MacGowan M., Mann M., Kormos M., Feldman M., Murali M. 1997. Circulating Interleukin-6 in Severe Heart Failure. The American Journal of Cardiology. 79 (8), 1128−1131.
- Bozkurt B.5 Kribbs S.B., Clubb F.J. Jr, et al. 1998. Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 97 (14), 1382−1391.
- Shen J., O’Brien D., Xu Y. 2006. Matrix metalloproteinase-2 contributes to tumor necrosis factor alpha induced apoptosis in cultured rat cardiac122myocytes. Biochemical and Biophysical Research Communications. 347 (4), 1011−1020.
- Krown K.A., Page M.T., Nguyen C., et al. 1996. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. J. Clin. Invest. 98 (12), 2854−2865.
- Cleutjens J.P.M., Kandala J.C., Guarda E., Guntaka R.V., Weber K.T. 1995. Regulation of collagen degradation in the rat myocardium after infarction. Journal of Molecular and Cellular Cardiology. 27 (6), 1281−1292.
- Natanson C., Eichenholz P.W., Danner R.L., et al. 1989. Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. The Journal of Experimental Medicine. 169 (3), 823 -832.
- Castagnoli C., Stella M., Berthod C., Magliacani G., Richiardi P.M. 1993. TNF Production and Hypertrophic Scarring. Cellular Immunology. 147 (1), 51−63.
- Pagani F.D., Baker L.S., Hsi C., et al. 1992. Left ventricular systolic and diastolic dysfunction after infusion of tumor necrosis factor-alpha in conscious dogs. J. Clin. Invest. 90 (2), 389−398.
- Gottschall P.E., Yu X. 1995. Cytokines regulate gelatinase A and B (matrix metalloproteinase 2 and 9) activity in cultured rat astrocytes. J. Neurochem. 64(4), 1513−1520.
- Wilson A.G., de Vries N., Pociot F., et al. 1993. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is stronglyassociated with HLA Al, B8, and DIG alleles. J. Exp. Med. Ill (2), 557 560.
- Kroeger K.M., Carville K.S., Abraham L.J. 1997. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol. Immunol. 34 (5), 391−399.
- Sallakci N., Akcurin G., Koksoy S., et al. 2005. TNF-alpha G-308A polymorphism is associated with rheumatic fever and correlates with increased TNF-alpha production. Journal of Autoimmunity. 25 (2), 150−154.
- Wilson A.G., Symons J.A., McDowell T.L., McDevitt H.O., Duff G.W. 1997. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc. Natl. Acad. Sci. U.S.A. 94 (1), 3195−3199.
- Allen R.D. 1999. Polymorphism of the human TNF-alpha promoter—random variation or functional diversity? Mol. Immunol. 36 (15−16), 1017−1027.
- Cox A., Gonzalez A.M., Wilson A.G., et al. 1994. Comparative analysis of the genetic associations of HLA-DR3 and tumour necrosis factor alpha with human IDDM. Diabetologia. 37 (5), 500−503.
- Peng J., Liu C., Zhu K., et al. 2003. The TNF2 allele is a risk factor to severe aplastic anemia independent of HLA-DR. Hum. Immunol. 64 (9), 896−901.
- Zou Y.-F., Feng X.-L., Tao J.-H., et al. 2010. Meta-analysis of TNF-alpha promoter -308A/G polymorphism and SLE susceptibility in Asian populations. Rheumatol. Int. .
- Никитин Ю.П., Рымар О. Д., Максимов B.H., et al. 2009. Полиморфизм G (-308)A гена TNF, связь с аутоимунными заболеваниями щитовидной железы в популяции Новосибирска. Бюллетень Сибирского отделения Российской академии медицинских наук. (1), 69−73.
- McGuire W., Hill A.V., Allsopp С.Е., Greenwood B.M., Kwiatkowski D. 1994. Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. Nature. 371 (6497), 508−510.
- Cabrera M., Shaw M.A., Sharpies C., et al. 1995. Polymorphism in tumor necrosis factor genes associated with mucocutaneous leishmaniasis. J. Exp. Med. 182 (5), 1259−1264.
- Herrmann S.M., Ricard S., Nicaud V., et al. 1998. Polymorphisms of the tumour necrosis factor-alpha gene, coronary heart disease and obesity. Eur. J. Clin. Invest. 28 (1), 59−66.
- Zhang H.-F., Xie S.-L., Wang J.-F., et al. 2011. Tumor necrosis factor-alpha G-308A gene polymorphism and coronary heart disease susceptibility: An updated meta-analysis. Thromb Res. .
- Schneider K., Potter K.G., Ware C.F. 2004. Lymphotoxin and LIGHT signaling pathways and target genes. Immunol. Rev. 202, 49−66.
- Ware C.F. 2005. Network communications: lymphotoxins, LIGHT, and TNF. Annu. Rev. Immunol. 23, 787−819.
- Ozaki K., Ohnishi Y., Iida A., et al. 2002. Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet. 32 (4), 650−4.
- Laxton R., Pearce E., Kyriakou T., Ye S. 2005. Association of the lymphotoxin-alpha gene Thr26Asn polymorphism with severity of coronary atherosclerosis. Genes Immun. 6 (6), 539−41.
- Keso T., Perola M., Laippala P., et al. 2001. Polymorphisms within the tumor necrosis factor locus and prevalence of coronary artery disease in middle-aged men. Atherosclerosis. 154 (3), 691−697.
- Yamada A., Ichihara S., Murase Y., et al. 2004. Lack of association of polymorphisms of the lymphotoxin alpha gene with myocardial infarction in Japanese. J. Mol. Med. 82 (7), 477−483.
- Koch W., Kastrati A., Bottiger C., et al. 2001. Interleukin-10 and tumor necrosis factor gene polymorphisms and risk of coronary artery disease and myocardial infarction. Atherosclerosis. 159 (1), 137−144.
- Suzuki G., Izumi S., Hakoda M., Takahashi N. 2004. LTA 252G allele containing haplotype block is associated with high serum C-reactive protein levels. Atherosclerosis. 176 (1), 91−94.
- R Development Core Team. 2010. R: A Language and Environment for Statistical Computing. Vienna, Austria: .
- Hald A. 1949. Maximum likelihood estimation of the parameters of a normal distribution which is truncated at a known point. Skandinavisk Aktuarietidskrift., 119−134.
- Berkson J., Gage R.R. 1950. The calculation of survival rates for cancer. Proceedings of Staff Meetings, Mayo Clinic. 25, 250.
- Cutler S.J., Ederer F. 1958. Maximum utilization of the life table method in analyzing survival. Journal of Chronic Diseases. (8), 699−712.
- Gehan E.A., Thomas D.G. 1969. The performance of some two sample tests in small samples with and without censoring. Biometrika. 56, 127−132.
- Barlow RE. 1963. Properties of Probability Distributions with Monotone Hazard Rate. Ann. Math. Statist. 34 (2), 375−389.
- Kaplan E.L., Meier P. 1958. Nonparametric Estimation from Incomplete Observations. Journal of the American Statistical Association. 53 (282), 457 481.
- Lee E.T., Desu M.M. 1972. A computer program for comparing К samples with right-censored data. Computer Programs in Biomedicine. 2 (4), 315 321.
- Mantel N. 1967. Ranking procedures for arbitrarily restricted observation. Biometrics. 23 (1), 65−78.
- Анализ выживаемости http://www.statsoft.ru/home/textbook/default.htm.
- The Official Microsoft ASP.NET Site http://www.asp.net/.
- Roberts R.J., Vincze Т., Posfai J., Macelis D. 2010. REBASE—a database for DNA restriction and modification: enzymes, genes and genomes. Nucleic Acids Res. 38, D234-D236.
- SibEnzyme http://russia.sibenzyme.com/.
- Компания Helicon: Ферменты и белки Fermentas http://helicon.ru/catalog/section.php?IBLOCKID=6&SECTIONID=278.
- Gehring N.H., Frede U., Neu-Yilik G., et al. 2001. Increased efficiency of mRNA 3' end formation: a new genetic mechanism contributing to hereditary thrombophilia. Nat. Genet. 28 (4), 389−392.
- Lozanski G., Jiang S.L., Samols D., Kushner I. 1996. C-reactive protein and serum amyloid A mRNA stability following induction by cytokines. Cytokine. 8 (7), 534−540.
- Post L.E., Strycharz G.D., Nomura M., Lewis H., Dennis P.P. 1979. Nucleotide sequence of the ribosomal protein gene cluster adjacent to the gene for RNA polymerase subunit beta in Escherichia coli. Proc. Natl. Acad. Sci. U.S.A. 76 (4), 1697−1701.
- Shen L.X., Basilion J.P., Stanton V.P. Jr. 1999. Single-nucleotide polymorphisms can cause different structural folds of mRNA. Proc. Natl. Acad. Sci. U.S.A. 96 (14), 7871−7876.
- Mysliwska J., Wieckiewicz J., Hak L., et al. 2006. Interleukin 6 polymorphism corresponds to the number of severely stenosed coronary arteries. Eur. Cytokine Netw. 17 (3), 181−8.
- Antonicelli R., Olivieri F., Bonafe M., et al. 2005. The interleukin-6 -174 G>C promoter polymorphism is associated with a higher risk of death after an acute coronary syndrome in male elderly patients. Int J Cardiol. 103 (3), 266−71.
- Terry C.F., Loukaci V., Green F.R. 2000. Cooperative Influence of Genetic Polymorphisms on Interleukin 6 Transcriptional Regulation. Journal of Biological Chemistry. 275 (24), 18 138−18 144.
- Rivera-Chavez F.A., Peters-Hybki D.L., Barber R.C., O’Keefe G.E. 2003. Interleukin-6 promoter haplotypes and interleukin-6 cytokine responses. Shock. 20 (3), 218−223.
- Adams D.H., Shaw S. 1994. Leucocyte-endothelial interactions and regulation of leucocyte migration. The Lancet. 343 (8901), 831−836.
- Zhou X., Stemme S., Hansson G.K. 1996. Evidence for a local immune response in atherosclerosis. CD4+ T cells infiltrate lesions of apolipoprotein-E-deficient mice. Am. J. Pathol. 149 (2), 359−366.
- Huber S.A., Sakkinen P., Conze D., Hardin N., Tracy R. 1999. Inteiieukin-6 Exacerbates Early Atherosclerosis in Mice. Arterioscler Thromb Vase Biol. 19 (10), 2364−2367.
- Heinisch R.H., Zanetti C.R., Comin F., et al. 2005. Serial changes in plasma levels of cytokines in patients with coronary artery disease. Vascular Health and Risk Management. 1 (3), 245−50.
- Pai J.K., Mukamal K.J., Rexrode K.M., Rimm E.B. 2008. C-Reactive Protein (CRP) Gene Polymorphisms, CRP Levels, and Risk of Incident Coronary Heart Disease in Two Nested Case-Control Studies. PLoS ONE. 3 (1), el395.
- Mallat Z., Besnard S., Duriez M., et al. 1999. Protective Role of Interleukin-10 in Atherosclerosis. Circ Res. 85 (8), el7−24.
- Pinderski Oslund L.J., Hedrick C.C., Olvera T., et al. 1999. Interleukin-10 Blocks Atherosclerotic Events In Vitro and In Vivo. Arterioscler Thromb VascBiol. 19 (12), 2847−2853.
- Von Der Thusen J.H., Kuiper J., Fekkes M.L., et al. 2001. Attenuation of atherogenesis by systemic and local adenovirus-mediated gene transfer of interleukin-10 in LDLr-/- mice. FASEB J. 15 (14), 2730−2732.
- Malarstig A., Eriksson P., Hamsten A., et al. 2008. Raised interleukin-10 is an indicator of poor outcome and enhanced systemic inflammation in patients with acute coronary syndrome. Heart. 94 (6), 724−729.
- Plutzky J. 2001. Inflammatory pathways in atherosclerosis and acute coronary syndromes. The American Journal of Cardiology. 88 (8, Supplement 1), 10−15.
- Clarke R., Xu P., Bennett D., et al. 2006. Lymphotoxin-alpha gene and risk of myocardial infarction in 6,928 cases and 2,712 controls in the ISIS case-control study. PLoS Genet. 2 (7), el07.